While Senseonics (NYSE:SENS) stock has a great deal of potential, the shares currently have a fairly high valuation. Source: Minerva Studio / Shutterstock.com Moreover, in the short-term and medium-term, SENS stock looks poised to fall significantly. Senseonics has developed Eversense, a 90-day continuous glucose monitoring (CGM) system. According to the company, the device provides continuous glucose monitoring for up to 90 days after being inserted under the skin of diabetes patientsInvestorPl
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 866 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F […]
Dexcom's (DXCM) CGM is expected to simplify diabetes management due to increasing access to the life-changing technology.